Company profilePharmaceutical#35 of 1,318 in Pakistan1 DRAP alert

SAFFRON PHARMACEUTICAL COMPANY

Pharmaceutical company · 283 brands · 236 molecules

Ranked #4 of 58 companies in Skin Conditions

283 registered products 79 pharmaceutical brands 236 distinct molecules 1 DRAP alert

Company overview

283
registered products
79
pharmaceutical brands
236
distinct molecules
12
therapeutic classes
1
DRAP alerts

SAFFRON PHARMACEUTICAL COMPANY is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 283 product registrations across 236 distinct molecules. It is the 35th largest registrant in Pakistan by product count, and ranks 4th of 58 in Skin Conditions. Its portfolio is concentrated in Skin Conditions and Blood Glucose Lowering Drugs, Excluding Insulin. DRAP has issued 1 alert involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by SAFFRON

203 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

116
ceilings with an approval date
1
not revised in 2+ years
2024
oldest approval year
20241
20252
2026113
Longest without revision

Top molecules by brand count

Therapeutic classes

Skin Conditions · 16Blood Glucose Lowering Drugs, Excluding Insulin · 6Antiinflammatory And Antirheumatic Products · 6Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 6Anti-Infectives · 6Corticosteroid Combinations, Topical · 5Anti-Acne Preparations · 5Antianemic, Iron Preparations · 5Quinolone Antibacterials · 5Corticosteroid, Plain · 4Allergy · 3Antihistamines For Systemic Use · 3

Conditions treated

Eczema/Psoriasis/Dermatitis · 13General Infections · 4Ulcer/Reflux/Flatulence/Acidity · 3Acne/Topical · 2Pain Killers · 2Fungal Infection · 2Nasal Congestion · 2Oral Agents · 2Conventional Agents · 1Hormonal Therapy · 1Asthma/Allergy · 1Bladder & Prostate Disorder · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official223 products · Rs 8.02 – Rs 49,634.86
DVAGO75 products · Rs 71.3 – Rs 1,315.02
Servaid53 products · Rs 53.2 – Rs 700
Median across source: Rs 232.8

Regulatory record

1 alert in the DRAP feed we track.

Voluntary Recall Alert: Drug Product; Cytotol 200mcg Tablets (Batch # 176,177,178,179,180)
2022-12-22

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

GETZ PHARMA PAKISTAN (PVT) LTD. holds 213 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole
NEUTRO PHARMA (PVT) LTD. holds 89 molecules not in this portfolio
AcyclovirAlbendazoleAnastrazoleAnastrozoleAntimonyAripiprazole
Atco Pharma International (Pvt) Ltd holds 184 molecules not in this portfolio
Acetylsalicylic AcidAcyclovirAdapleneAlbuterolAminophyllineAmlodipine 6.95Mg Amlodipine Base

Get the full profile for SAFFRON

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.